On June 14, 2024, the U.S. FDA approved AstraZeneca’s Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.
Wolters Kluwer Unveils Generative AI Labs for UpToDate
What You Should Know: Wolters Kluwer Health has launched AI Labs, a collaborative resource that brings the power of generative AI to UpToDate, its market leading
October 3, 2023